Clinical trial · no report yet · Phase 2
NCT06312670
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
- NCT06312670 ↗
- Completed
- Pedro Barata, MD, MSc
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 5 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase 2 Trial Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Prostate Cancer; Prostate Adenocarcinoma
- Interventions
- EPI-7386; Enzalutamide; Androgen Deprivation Therapy (ADT)
- Arms
- EPI-7386 + Enzalutamide · Experimental
- Enrollment
- 13
- Primary outcomes
- Biochemical response rate
- PSA progesterone-free survival (PFS)
- Radiographic PFS (rPFS)
- ORR (confirmed)
- Sponsor
- Pedro Barata, MD, MSc with ESSA Pharma Inc.
- Start
- May 16, 2024
- Primary completion
- Jan 9, 2025
- Results posted
- No
- Registry record
- NCT06312670 · updated May 29, 2025
Publications
linked from the registry- Jang A, Fowler P, Helminiak K, Kumar HLS, Pasucal J, Delong V, Zhong JY, Jindal T, Grier AL, Patel RR, Hislop M, Cesano A, Villaluna K, Younginger B, Wolff K, Richey K, Bray J, Garcia H, Adamowicz T, Reese A, Nizam A, Gupta S, Wee CE, Margevicius S, Fu P, Mendiratta P, Sheng IY, Brown JR, Garcia JA, Barata PC. EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naive metastatic hormone-sensitive prostate cancer. Oncologist. 2026 Jan 17;31(2):oyaf434. doi: 10.1093/oncolo/oyaf434. PubMed 41467749